{"brief_title": "Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy", "brief_summary": "The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.", "condition": ["Parkinson's Disease"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Carbidopa/levodopa/entacapone", "Immediate release carbidopa/levodopa"], "description": ["Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.", "Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules."], "arm_group_label": ["Carbidopa/levodopa/entacapone", "Immediate release carbidopa/levodopa"], "other_name": ["Stalevo", "Sinemet"], "criteria": "Inclusion Criteria: - Clinical diagnosis of idiopathic Parkinson's disease - Diagnosis of Parkinson's disease for no more than 5 years Exclusion Criteria: - History, signs, or symptoms of atypical or secondary parkinsonism - Presence at baseline of drug-related wearing-off symptoms, dyskinesia or other motor complications - Levodopa exposure of more than 30 days or anytime within 8 weeks prior to visit 1 Other inclusion/exclusion criteria applied to this study.", "gender": "All", "minimum_age": "30 Years", "maximum_age": "70 Years", "healthy_volunteers": "No", "keyword": "Parkinson's disease, levodopa therapy, dyskinesia", "mesh_term": ["Parkinson Disease", "Carbidopa", "Carbidopa, levodopa drug combination", "Levodopa", "Entacapone"], "id": "NCT00099268"}